All previous studies of the sub-acute effects of ecstasy have failed to adequately control for group differences in psychopathology and past and concurrent substance use. The present study was designed to avoid these limitations. At an initial pre-drug baseline, a sample of 38 regular ecstasy users provided full substance histories and completed measures of personality and self-reported psychopathology. We then collected daily subjective measures of mood, cognitive impairment, restless sleep, sexual desire, craving for ecstasy and concomitant use of other substances for the next 9 days. The 20 participants who subsequently opted to take ecstasy during the 9-day assessment period reported modest sub-acute effects of ecstasy on negative mood and subjective cognitive impairment compared to those who did not after controlling for baseline group differences in psychopathology and frequency of ecstasy use. There were no signi.cant sub-acute effects of ecstasy on interest in sexual activity or craving for ecstasy. After further controlling for co-use of alcohol with ecstasy, and the sub-acute effects of ecstasy on sleep, the sub-acute effect on mood remained marginally statistically signi.cant but the subacute effect on cognitive impairment did not. The present .ndings suggest that the sub-acute effects of ecstasy in regular recreational users are relatively modest and transient but that such genuine effects may have been masked by, perhaps more clinically signi.cant, chronic sequelae of regular ecstasy use in all previous studies of recreational ecstasy users.
Allen R P, McCann U D, Ricuarte G A (1993) Persistent effects of (±) 3,4-methylene-dioxymethamphetamine (MDMA, ‘Ecstasy’) on human sleep. Sleep16: 560–564
2.
Balogh B, Molnar E, Jakus R, Quate L, Olverman H J, Kelly P A, Kantor S, Bagdy G (2004) Effects of a single dose of 3,4-methylenedioxymethamphetamine on circadian patterns, motor activity and sleep in drug-naïve rats and rats previously exposed to MDMA. Psychopharmacology173: 296–309
3.
Beck A T, Ward C H, Mendelson M, Mock J, Erbaugh J (1961) An inventory for measuring depression. Arch Gen Psychiatry4: 561–571
4.
Biello S M, Dafters R I (2001) MDMA and fenfluramine alter the response of the circadian clock to a serotonin agonist in vitro. Brain Res920: 202–209
5.
Cohen R S (1995) Subjective reports of the effects of the MDMA (‘Ecstasy’) experience in humans. Prog Neuropsychopharm Biol Psychiat19: 1137–1145
6.
Colbron S, Jones M, Biello S M (2002) MDMA alters the response of the circadian clock to a photic and non-photic stimulus. Brain Res956: 45–52
7.
Cottler L B, Womack S B, Compton W M, Ben-Abdallah A (2001) Ecstasy abuse and dependence among adolescents and young adults: applicability and reliability of DSM-IV criteria. Hum Psychopharmacol16: 599–606
8.
Curran H V, Travill R A (1997) Mood and cognitive effects of 3,4-methylenedioxymeth-amphetamine (MDMA, ‘Ecstasy’): week-end ‘high’ followed by mid-week low. Addiction92: 821–831
9.
Curran H V, Rees H, Hoare T, Hoshi R, Bond A (2004) Empathy and aggression: two faces of ecstasy? A study of interpretative cognitive bias and mood change in ecstasy users. Psychopharmacology173: 425–433
10.
Daumann J, Hensen G, Thimm B, Rezk M, Till B, Gouzoulis-Mayfrank E (2004) Self reported psychopathological symptoms in abstinent recreational ecstasy (MDMA) users are mainly associated with regular cannabis use: further evidence from a combined crosssectional/longitudinal investigation. Psychopharmacology173: 398–404
11.
Davison D, Parrott A C (1997) Ecstasy (MDMA) in recreational users: self-reported psychological and physiological effects. Hum Psychopharmacol Clin & Exper12: 221–226
12.
Derogatis L R (1994) The SCL-90 scoring manual. Johns Hopkins School of Medicine, Clinical Psychometrics Unit, Baltimore, MA
13.
Elman I, Karlsgodt K H, Gastfriend D R (2001) Gender differences in cocaine craving among non-treatment-seeking individuals with cocaine dependence. Am J Drug Alcohol Abuse27: 193–202
14.
Eysenck H J, Eysenck S B G (1991) Adult Impulsiveness, Venturesomeness and Empathy Scale. Hodder & Stoughton Ltd, London
15.
Gamma A, Frei E, Lehmann D, Pascual R D, Hell D, Vollenweider F X (2000) Mood state and brain electric activity in Ecstasy users. Neuroreport11: 157–162
16.
Gerra G, Zaimovic A, Giucastro G, Maestri D, Monica C, Sartori R, Caccauari R, Delsignore R (1998) Serotonergic function after 3,4-methylenedioxymethamphetamine (‘Ecstasy’) in humans. Int Clin Psychopharm13: 1–9
17.
Gerra G, Zaimovic A, Ferri M, Zambelli U, Timpano M, Neri E, Marzocchi G F, Delsignore R, Brambilla F (2000) Long-lasting effects of 3,4-methylenedioxymethamphetamine (Ecstasy) on serotonin system function in humans. Biol Psychiat47: 127–136
18.
Gonzalez R, Rippeth J D, Carey C L, Heaton R K, Moore D J, Schweinsburg B C, Cherner M, Grant I (2004) Neurocognitive performance of methamphetamine users discordant for history of marijuana exposure. Drug Alcohol Depend76: 181–190
19.
Groth-Marnat G (1990). The handbook of psychological assessment2nd edn.John Wiley & Sons, New York
20.
Henry J A (1992) Ecstasy and the dance of death. BMJ305: 5–6
21.
Hoshi R, Bisla J, Curran H V (2004) The acute and sub-acute effects of ‘ecstasy’ (MDMA) on processing of facial expressions: preliminary findings. Drug Alcohol Depend76: 297–304
22.
Jansen K L (1999) Ecstasy (MDMA) dependence. Drug Alcohol Depend53: 121–124
23.
Lieb R, Schuetz C G, Pfister H, von Sydow K, Wittchen H-U (2002) Mental disorders in ecstasy users; a prospective-longitudinal investigation. Drug Alcohol Depend68: 195–207
24.
Liechti M E, Vollenweider F X (2000a) The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine (‘Ecstasy’) in healthy volunteers. J Psychopharmacol14: 269–274
25.
Liechti M E, Vollenweider F X (2000b) Acute psychological and physiological effects of MDMA (‘Ecstasy’) after haloperidol pretreatment in healthy humans. Eur Neuropsychopharmacol10: 289–295
26.
Liechti M E, Saur M R, Gamma A, Hell D, Vollenweider F X (2000) Psychological and physiological effects of MDMA (‘Ecstasy’) after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans. Neuropsychopharm23: 396–404
27.
Morgan M J (1998) Recreational use of ‘ecstasy’ (MDMA) is associated with elevated impulsivity. Neuropsychopharmacol19: 252–264
28.
Morgan M J (1999) Memory deficits associated with recreational use of ‘ecstasy’ (MDMA). Psychopharmacology141: 30–36
29.
Morgan M J (2000) Ecstasy (MDMA): a review of its possible persistent psychological effects. Psychopharmacology152: 230–248
30.
Morgan M J, McFie L, Fleetwood H, Robinson J A (2002) Ecstasy (MDMA): are the psychological problems associated with its use reversed by prolonged abstinence?Psychopharmacology159: 294–303
31.
Parker G, Roy K (2003) The development of a six-item daily self-report measure assessing identified depressive domains. J Affect Disord73: 289–294
32.
Parrott A C (2001) Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research. Hum Psychopharmacol16: 557–577
33.
Parrott A C, Lasky J (1998) Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance. Psychopharmacology139: 261–268
34.
Parrott A C, Sisk E, Turner J J D (2000) Psychobiological problems in heavy ‘Ecstasy’ (MDMA) polydrug users. Drug Alcohol Depend60: 105–110
35.
Peroutka S J, Newman H, Harris H (1988) Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacol1: 273–277
36.
Saunders N (1997) Ecstasy Reconsidered. Nicholas Saunders, London
37.
Schifano F (1991) Chronic atypical psychosis associated with MDMA (‘ecstasy’) abuse. Lancet338: 1335-1335
38.
Schifano F, Di Furia L, Forza G, Minicuci N, Bricolo R (1998) MDMA (‘ecstasy’) consumption in the context of polydrug abuse: a report on 150 patients. Drug Alcohol Depend52: 85–90
39.
Solowij N, Hall W, Lee N (1992) Recreational MDMA use in Sydney: a profile of ‘Ecstasy’ users and their experiences with the drug. Brit J Addict87: 1161–1172
40.
Thomasius R, Petersen K, Buchert R, Andresen B, Zapletalova P, Wartberg L, Nebeling B, Schmoldt A (2003) Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users. Psychopharmacology167: 85–96
41.
Topp L, Hall W, Hando J (1997) Is there a dependence syndrome for ecstasy?National Drug and Alcohol Research Centre Technical Report Number 51. National Drug and Alcohol Research Centre, Sydney
42.
Topp L, Hando J, Dillon P, Roche A, Solowij N (1999) Ecstasy use in Australia: patterns of use and associated harm. Drug Alcohol Depend55: 105–115
43.
Verheyden S L, Henry J, Curran H V (2003a) Acute, sub-acute and longterm subjective consequences of ecstasy (MDMA) consumption in 430 regular users. Hum Psychopharmacol18: 507–517
44.
Verheyden S L, Maidment R, Curran H V (2003b) Quitting ecstasy: an investigation of why people stop taking the drug and their subsequent mental health. Psychopharmacology174: 371–378
45.
Verheyden S L, Hadfield J, Calin T, Curran H V (2002) Sub-acute effects of MDMA (± 3,4-methylnedioxymethamphetamine, ‘ecstasy’) on mood: evidence of gender differences. Psychopharmacology161: 23–31
46.
Vollenweider F X, Gamma A, Liechti M, Huber T (1998) Psychological and cardiovascular effects and short-term sequelae of MDMA (‘Ecstasy’) in MDMA-naïve healthy volunteers. Neuropsychopharmacol19: 241–251
47.
von Sydow K, Lieb R, Pfister H, Hofler M, Wittchen H U (2002) Use, abuse and dependence of ecstasy and related drugs in adolescents and young adults – a transient phenomenon? Results from a longitudinal community study. Drug Alcohol Depend66: 147–159
48.
Winstock A, Griffiths P, Stewart D (2001) Drugs and the dance music scene: a survey of current drug use patterns among a sample of dance music enthusiasts in the UK. Drug Alcohol Depend64: 9–17
